Clinical Trials Browser

Fibrolamellar hepatocellular carcinoma × Specimen Handling × 90 days × Clear all

NCT06620302 2026-02-24

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1/2 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma

NCT03533582 2025-12-22

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Phase 3 Active not recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Hepatoblastoma